The prognosis for patients with metastatic renal cell carcinoma may be brightening. Immunotherapy may offer an effective alternative approach for this disease. Continuing advances in immunology and molecular biology will probably reinforce the early enthusiasm for this method. Although still investigational, cytokine monotherapy and combination therapy, adoptive immunotherapy, and gene therapy appear to be promising therapeutic modalities for selected patients with metastatic renal cell carcinoma.